Arterial thromboembolism (TE) in the absence of current or recent history of a central catheter is a rare condition in newborn period. We report a case of severe lower extremities arterial TE of unclear etiology in a full-term neonate. By adding hyperbaric oxygenation to thrombolytic and antithrombotic therapy, we achieved improved perfusion of the upper leg tissues, preserving the knee and enabling below-the-knee amputation.
Introduction
Arterial thromboembolic (TE) events, rare in the neonatal period, may lead to irreversible organ damage and loss of limbs. 1 We are reporting the case of a newborn infant with acute arterial thromboembolism of both legs, including the presentation, physical and diagnostic findings, and response to treatment. By adding hyperbaric oxygenation (HBOT) to thrombolytic and antithrombotic therapy of upper and lower leg arterial thromboses we achieved improved perfusion of the upper leg tissues, preventing above the knee amputation.
Case presentation
The patient was a 3211 g full-term AGA male newborn born via scheduled repeat C-section to a 28-year-old G5P3 mother. Aside from a positive group B streptococcus (GBS) cervical culture, other maternal prenatal screening laboratories were unremarkable, including glucose tolerance testing. Both prenatal ultrasounds failed to show any presence of a cord or amniotic band encircling the extremities. The membranes were ruptured at the time of delivery. Apgar scores were 8 and 8 at 1 and 5 min, respectively. Upon arrival at the tertiary center, the infant required highfrequency ventilation and inhaled nitric oxide (iNO) due to poor oxygenation. Dopamine and dobutamine drips were required to sustain appropriate blood pressure. The infant was kept comfortable on a Fentanyl drip and Ativan doses as needed for pain control. An umbilical venous line was placed for administration of therapy. An umbilical arterial line was attempted in order to perform an aortogram to assess the extent of the thrombus, however, this was unsuccessful. The patient was treated with anti-thrombin 3, heparin drip and tissue plasminogen activator (tPA). Nitroglycerin paste was applied to lower extremities in the femoral and popliteal region in an attempt of improving arterial blood flow.
By day of life (DOL) No. 7, perfusion of left leg and respiratory status were markedly improved. Patient was changed from high frequency to conventional ventilation and iNO was discontinued. However, the right leg was still severely compromised, with pale-bluish discoloration starting at the upper thigh, no distal pulses, sloughing skin and necrotic changes of the toes (Figure 1 ). It appeared that below the hip amputation would be inevitable. Bedside testing, however, determined the right leg tissue TcPO 2 responded to higher FiO 2 . As the patient was clinically more stable, the decision was made to start HBOT therapy to improve perfusion of the leg tissues in an attempt to salvage the right knee, since functional prognosis after below-the-knee (BTK) amputation differs greatly from the above-the-knee amputation. After the first HBOT treatment there was noticeable improvement in tissue perfusion and better demarcation of borders of viable and necrotic tissue (Figure 1) . The infant was placed in a hyperbaric chamber with 2 atm of pressure for 60 min daily on weekdays between DOL No. 7 and DOL No. 20. Following completion of HBOT (Figure 2) , repeat Doppler studies confirmed the patency of the right common, superficial, profunda femoralis and popliteal arteries, although with lower than normal resistive indices. However, the right posterior tibial arterial flow did not recover.
The infant was weaned off vasopressor support by DOL No. 11 and off oxygen by DOL No. 24. Daily head ultrasounds were negative. Magnetic resonance imaging of the brain was normal and electroencephalography showed no seizure activity.
On DOL No. 28, the patient underwent a BTK amputation of the right lower extremity. Two weeks later he had a debridement of the wound with resection of the tibia and fibula, followed 1 week later by skin closure. Doppler studies before discharge showed patency of the right common and superficial femoral arteries and normal left lower extremity arterial flow.
On DOL No. 55 the infant was discharged home (Figure 3 ). In the neonatal intensive care unit follow-up clinic on DOL No. 98 all findings were within normal limits.
The hematology work-up for all congenital and acquired etiologies for thrombosis was negative in the patient; Factor V Leiden was 137.2% (normal >50%), Protein S 59% (normal 58-146%) and Protein C 46.4% (74.8-179%). The hematology work-up in the family was unremarkable.
The child at the time of this report was 22 months old ( Figure 4 ) and has had no further thrombosis or sequelae. He is developmentally appropriate for his age, walking and running without assistance, using a right BTK prosthesis. HBOT in treatment of neonatal arterial thromboembolism J Wieber et al Discussion TE occlusion of peripheral arteries is rare problem of newborn infants. 1 It can occur as a result of maternal diabetes, coagulopathies or, most commonly, complications of central catheter placement, 2 and is associated with birth anoxia, preeclampsia and congenital heart disease.
1 None of the above risk factors applied to this patient. The congenital prothrombotic disorders that have been linked to TEs in newborns include deficiencies of antithrombin, protein C, protein S and plasminogen and the presence of prothrombin gene 20210A and Factor V Leiden. 3 The methylene tetrahydrofolate reductase (MTHFR) C677T genotype found in our patient has been positively associated with arterial and venous thrombotic disease in some populations; however, this mutation alone may not sufficiently explain this arterial clot. 4, 5 The use of HBOT has been shown by several investigators to restore a favorable cellular environment for wound healing and support vascular proliferation by increasing the oxygen content of the plasma. 6, 7 HBOT is currently widely used for treatment of CO intoxication, arterial gas emboli, compromised skin flaps and grafts, radiation soft tissue necrosis, osteoradionecrosis and chronic non-healing wounds. Siraneci et al. 8 report the successful use of adjunctive HBOT in an infant with thrombotic purpura fulminans. In severe cases of ischemia unresponsive to heparin or thrombolytic therapy, fasciotomy and limb amputation may be inevitable. Mihaljevic et al. 9 suggested that combining HBOT and fibrolytic treatment of lower leg arterial thromboembolism potentially decreases ischemic pain, prolongs tissue survival, and thus justifies its use in cases of peripheral arterial TE.
Using HBOT we were able to avoid below-the-hip amputation in the neonate, allowing BTK amputation, with much better functional prognosis. Experience with use of HBOT as an adjunctive therapy in arterial TE is limited to a few case reports, including this one. This case suggests that vascular damage and compromise may still be reversible after 7 days. Promising results suggest that HBOT should be considered early as a useful adjunctive therapy in cases of severe arterial TE, particularly in newborns with ischemic limbs.
